# A Phase Ib/II Clinical Trial of M701 in the Treatment of Malignant Pleural Effusions Caused by NSCLC

Source: https://onco.cc/trials/nct05543330/  
OnCo record `nct05543330` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Cisplatin in non-small-cell lung cancer, run by Wuhan YZY Biopharma Co., Ltd., now recruiting.

## Summary

A Phase Ib/II Clinical Trial of M701 in the Treatment of Malignant Pleural Effusions Caused by NSCLC is a phase 1/2 interventional study registered as NCT05543330 by Wuhan YZY Biopharma Co., Ltd., with 116 participants planned, started 2022-09-30 and due to reach its primary completion in 2026-09-15. Interventions recorded: M701 pleural infusion, Pleural drainage and Cisplatin pleural infusion.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05543330
- Phase: 1/2
- Setting: A Phase 1, Multicenter, Open-label, Dose-increasing Study to Evaluate the Safety, Tolerability, PK/PD and Preliminary Efficacy of M701, a Recombinant Epcam and CD3 Bispecific Antibody , in Patients With Malignant Pleural Effusions Caused by NSCLC
- Sponsor: Wuhan YZY Biopharma Co., Ltd.
- Enrolled: 116

## Sources

- ClinicalTrials.gov NCT05543330: https://clinicaltrials.gov/study/NCT05543330

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [Cisplatin](https://onco.cc/drugs/cisplatin/)
- companies: [Wuhan YZY Biopharma](https://onco.cc/companies/wuhan-yzy-biopharma/)

---
JSON: https://onco.cc/api/v1/entities/nct05543330.json